← All companies
CRISPR Therapeutics AG
CRSP - CIK 0001674416
Market cap$4.77 B
Rank#1422
SEC filings837
CRISPR Therapeutics AG trades as CRSP and has a market capitalization of $4.77 B, making it the #1422 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.51M, down 90.6% from the prior year and net income of -$581.60M. This page tracks CRISPR Therapeutics AG through 837 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$3.51MFY 2025
Net income (latest FY)-$581.60MFY 2025
Operating cash flow (latest FY)-$345.01MFY 2025
Total assets (latest FY)$2.27BFY 2025
Net margin-16569.8%latest FY
Financial performance
Over the last 9 fiscal years CRISPR Therapeutics AG's revenue declined from $5.16M to $3.51M, a compound annual decline rate of 4.2%. Net profit margin compressed from -448.8% to -16569.8% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $4.77 B
- Share price (derived)market cap / shares outstanding
- $49.44
- EPS (diluted)FY 2025
- $-6.47
- Shares outstandingas of 2026-04-30
- 0.10B
- Total equityas of 2026-03-31
- $1.81B
- Return on equity
- -32.1%
- Long-term debtas of 2026-03-31
- $585.47M
- Cash & equivalentsas of 2026-03-31
- $423.31M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G/A | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-21 |
| Proxy materials | DEFA14A | 2026-04-21 |
| Proxy statement | DEF 14A | 2026-04-21 |
Recent press releases
- CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference2026-05-06
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results2026-05-04
- CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference2026-04-07
- CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering2026-03-11
- CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering2026-03-10
Similar companies
The largest companies sharing CRISPR Therapeutics AG's SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is CRISPR Therapeutics AG's market cap?
CRISPR Therapeutics AG (CRSP) has a market capitalization of $4.77 B as of 2026-06-10, ranking #1422 among US-listed companies.
How much revenue does CRISPR Therapeutics AG make?
CRISPR Therapeutics AG reported revenue of $3.51M for fiscal year 2025, a decrease of 90.6% year over year.
Is CRISPR Therapeutics AG profitable?
In its latest fiscal year CRISPR Therapeutics AG reported a net loss of $581.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.